HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $235,000 | -14.9% | 5,333 | -22.9% | 0.00% | 0.0% |
Q1 2022 | $276,000 | -0.7% | 6,917 | +0.0% | 0.00% | 0.0% |
Q4 2021 | $278,000 | -10.3% | 6,914 | -9.2% | 0.00% | 0.0% |
Q3 2021 | $310,000 | -10.7% | 7,611 | -0.3% | 0.00% | -50.0% |
Q2 2021 | $347,000 | -48.8% | 7,632 | -53.0% | 0.00% | 0.0% |
Q1 2021 | $678,000 | +88.9% | 16,252 | +93.5% | 0.00% | 0.0% |
Q4 2020 | $359,000 | – | 8,401 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |